Navigation Links
Antigen Express' AE37 Cancer Vaccine Featured in Scientific American
Date:9/21/2011

WORCESTER, Mass. and TORONTO, Sept. 21, 2011 /PRNewswire/ -- Generex Biotechnology Corporation's (OTCBB: GNBT) (www.generex.com) wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), today announced that its lead drug candidate AE37, a novel HER-2/neu-targeted vaccine currently in Phase II development for the treatment of breast cancer, is featured in the October 2011 issue of Scientific American, in a story titled "A New Ally Against Cancer" by Eric von Hofe, Ph.D., President of Antigen Express (http://www.scientificamerican.com/article.cfm?id=a-new-ally-against-cancer).

(Logo:  http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)

The article highlights recent advances in the field of cancer immunotherapy. It describes how previous adoptive immunotherapy using just CD8+ cells had shown no benefit and that cancer vaccines would have to elicit both CD4+ and CD8+ cells to be effective. AE37 is also described as a peptide-based vaccine that uses bits of the HER-2/neu protein that are small in size, inexpensive to synthesize and very easy to manipulate, which means that they can be readily formulated into a vaccine that is simple to manufacture in large amounts. This is in stark contrast to autologous cell-based therapies, such as Provenge®, which are costly and labor intensive.

The article also states that in spite of previous obstacles and complexities, "the signs are clear:  a patient's own immune system can be effectively enlisted to help combat cancer."

"We are pleased to be featured in Scientific American to review our pioneering work in the field of cancer immunotherapy and look forward to future articles and peer reviewed publications docume
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
2. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
3. Medicago succesfully expresses VLP antigen for A H1N1 strain
4. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
5. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
6. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
7. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
8. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
9. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
10. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
11. Generex Provides Update on Spinout of Antigen Express
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy ... that it has signed a letter of intent ... has developed and patented a nanotechnology-based development platform ... products that enable rapid on-site collection and testing ... and health issues in an immediate, non-invasive and ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2
... assessment to be added to the, ... 28 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or "Company") ... on activities as well as an interim progress ... is conducting a human Phase 1b/2a clinical trial ...
... Sigma-Aldrich (Nasdaq: SIAL ) today announced the global ... provides a novel and powerful approach to RNAi screening in ... http://www.sigma.com/esirna ) incorporates a pool of hundreds of ... designed to eliminate the trial and error approach of identifying ...
... Techne Corporation,s (Nasdaq: TECH ) consolidated net ... to $27.6 million or $.74 per diluted share compared with ... ended March 31, 2008. For the nine months ended ... $79.9 million or $2.10 per diluted share compared with $76.3 ...
Cached Biology Technology:Resverlogix Provides Quarterly Update 2Resverlogix Provides Quarterly Update 3Resverlogix Provides Quarterly Update 4Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 2Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 3Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 4Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 2Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 3Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 4Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 5Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 6Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 7
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws ... efficiency are piloting the North American and European automotive ... accidents growing, gesture recognition systems that are intuitive and ... mark in the industry. New analysis ... Gesture Recognition Market in Europe ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... clever trick for overcoming sleep deprivation. Sam Ridgway from the ... to send half of their brains to sleep while the ... to be able to remain continually vigilant for sounds for ... colleagues from San Diego and Tel Aviv wonder whether the ...
... May 1, 2009 As people become more educated, studies ... lower in calories but higher in nutrients. They also pay ... of the Journal of the American Dietetic Association , ... and food costs of a sample of 164 adults in ...
... plants are constantly confronted with adverse environmental conditions, lowering ... use specialized signals, called stress hormones, to sense difficult ... Of the various stress hormones, abscisic acid ... last 30 years as the key hormone that helps ...
Cached Biology News:Dolphins maintain round-the-clock visual vigilance 2People of higher socioeconomic status choose better diets -- but pay more per calorie 2Synthetic chemical offers solution for crops facing drought 2Synthetic chemical offers solution for crops facing drought 3
Request Info...
Request Info...
... ml CELLection Dynabeads (4.5 m) coated with ... antigen EpCAM and DNase Releasing Buffer. ... epithelial tumour cells directly from blood, bone ... be enriched from bone marrow. Enriched cells ...
PHOTOMAN DIRECT COPY CAMERA, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: